Palisade Bio, Inc. (PALI) stock
PALINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.94−0.07 (-6.72%)
Close on Nov 18, 2026Market cap $164.18MP/E –Yield –
Palisade Bio operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Palisade Bio's operating income for the twelve months ending Jun 30, 2026 was -$35.35M. For fiscal 2025 it was -$18.06M. The highest annual figure on record is -$8.26M in fiscal 2018.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$18.06M | – |
| FY2024 | Dec 31, 2024 | -$14.86M | – |
| FY2023 | Dec 31, 2023 | -$13.07M | – |
| FY2022 | Dec 31, 2022 | -$15.72M | – |
| FY2021 | Dec 31, 2021 | -$41.85M | – |
| FY2020 | Dec 31, 2020 | -$9.30M | – |
| FY2019 | Dec 31, 2019 | -$8.63M | – |
| FY2018 | Dec 31, 2018 | -$8.26M | – |
| FY2017 | Dec 31, 2017 | -$13.31M | – |
| FY2016 | Dec 31, 2016 | -$20.64M | – |
| FY2015 | Dec 31, 2015 | -$19.16M | – |
| FY2014 | Dec 31, 2014 | -$17.44M | – |
| FY2013 | Dec 31, 2013 | -$12.52M | – |
| FY2012 | Dec 31, 2012 | -$10.16M | – |
| FY2011 | Dec 31, 2011 | -$12.99M | – |
| FY2010 | Dec 31, 2010 | -$15.18M | – |
| FY2009 | Dec 31, 2009 | -$10.47M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$11.70M | – |
| Q1 FY2026 | Mar 31, 2026 | -$10.75M | – |
| Q4 FY2025 | Dec 31, 2025 | -$9.98M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.92M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.84M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.31M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.38M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.59M | – |
| Q2 FY2024 | Jun 30, 2024 | -$4.21M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.67M | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.15M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.78M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.61M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.53M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.85M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.41M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.57M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.89M | – |
| Q4 FY2021 | Dec 31, 2021 | -$4.03M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.02M | – |
| Q2 FY2021 | Jun 30, 2021 | -$32.86M | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.95M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.25M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.82M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.84M | – |
| Q1 FY2020 | Mar 31, 2020 | -$1.99M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.13M | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.12M | – |
| Q2 FY2019 | Jun 30, 2019 | -$1.92M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.46M | – |
| Q4 FY2018 | Dec 31, 2018 | -$1.80M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.08M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.02M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.35M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.27M | – |
| Q3 FY2017 | Sep 30, 2017 | -$2.59M | – |
| Q2 FY2017 | Jun 30, 2017 | -$4.22M | – |
| Q1 FY2017 | Mar 31, 2017 | -$4.23M | – |
| Q4 FY2016 | Dec 31, 2016 | -$5.65M | – |
| Q3 FY2016 | Sep 30, 2016 | -$4.92M | – |
See a number that looks wrong?